Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT103A in Relapsed/Refractory Multiple Myeloma
NCT05698303Phase 1Not yet recruiting
- Sponsor
- Reindeer Biotech
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of equecabtagene autoleucel in multiple myeloma (MM), sponsored by Reindeer Biotech. Primary endpoints: Incidence and severity of adverse events up to 2 years, Incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) up to 2 years and 1 more. Planned start May 2023; status: not yet recruiting.
02
Drugs
equecabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05698303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698303.